West Pharmaceutical forecasts 2025 results below expectations, shares drop
West Pharmaceutical Services forecast full-year profit and revenue below Wall Street estimates on Thursday due to a strong dollar and as the medical equipment maker's clients reduce inventory levels,
West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance
West Pharmaceutical reported Q4 earnings and revenue above expectations but issued a weak 2025 forecast. William Blair reiterated its Outperform rating.
Why West Pharmaceutical Services, Inc. (WST) Went Down on Thursday
We recently compiled a list of the Weak Earnings, Outlook Drag Shares of These 10 Firms on Thursday. In this article, we are going to take a look at where West Pharmaceutical Services, Inc. (NYSE:WST) stands against the other stocks.
Why West Pharmaceutical Services (WST) Stock Is Nosediving
Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) fell 34.9% in the afternoon session after the company reported disappointing fourth-quarter 2024 results: its full-year revenue and earnings guidance fell short of Wall Street's estimates.
6WST : West Pharmaceutical Servs's Options Frenzy: What...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest West Pharmaceutical Servs options trades with real-time alerts from Benzinga Pro.
West Pharmaceutical Services 4Q Results Clear Estimates but 2025 Guidance Comes Up Short
For 2025, West Pharmaceutical guided for sales between $2.88 billion and $2.91 billion as well as adjusted earnings per-share in the range of $6 and $6.20. Analysts polled by FactSet expected $3.04 billion in sales and $7.45 a share in adjusted earnings.
West Pharmaceutical: Q4 Earnings Snapshot
(WST) on Thursday reported fourth-quarter profit of $130.1 million. The Exton, Pennsylvania-based company said it had net
Earnings call transcript: West Pharmaceutical Q4 2024 beats EPS forecast, stock drops
West Pharmaceutical Services Inc . (NYSE:WST) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.82 compared to the forecasted $1.72. Despite this positive earnings surprise,
West Pharma (WST) Stock Leads S&P 500 Rout with 38% Slump
West Pharmaceutical Services (WST) stock plummeted 38% on Thursday, making it the biggest decliner in the S&P 500. The sharp ...
West Pharma’s stock tanks 33% to lead S&P 500 decliners as guidance misses by a wide margin
West Pharmaceutical Services Inc.’s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of ...
This Pharma Stock Is Today’s Worst in the S&P 500. Here’s Why.
West Pharmaceutical Services stock sank Thursday after the company issued a full-year outlook that missed analysts’ expectations. Shares plunged 31% to $222.46, putting them on pace for their worst ...
West Pharmaceutical price target lowered to $285 from $355 at BofA
BofA lowered the firm’s price target on West Pharmaceutical (WST) to $285 from $355 and keeps a Buy rating on the shares after the company ...
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
Shares of West Pharmaceutical Services Inc. rose 7.84% to $214.73 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.01% to ...
West Pharmaceutical targets 2-3% organic sales growth for 2025, highlights GLP-1 market expansion
Q4 2024 Management View CEO Eric Green highlighted that the company achieved 3.3% organic revenue growth in Q4 2024, marking a return to quarterly growth. Notable drivers included strong performance ...
West Pharmaceutical upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded West Pharmaceutical (WST) to Buy from Hold with a $250 price target Maximize Your Portfolio with Data Driven ...